Ocuphire Pharma Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
§ -
Good morning. Hi, everyone. Thanks for joining on day two of the Oppenheimer Healthcare Conference here. My name is François Brisebois, I'm one of the biotech analysts at OpCo. It's my pleasure to introduce Ocuphire. Ocuphire is a clinical-stage ophthalmology company with programs in reversal of mydriasis, presbyopia, night vision disturbance, as well as issues at the back of eye like diabetic macular edema and diabetic retinopathy. So there is a pipeline here. So a lot of catalysts as well around the corner. So pretty timely discussion hopefully here.
So from the company, we have CEO Mina Sooch to present. In terms of format, what we'll do is we'll do a fireside chat. So feel free to send questions in the Q&A tab at the bottom of your screen. And I can't promise, but I'll do my best to get to them. So with that, Mina, thank you so much for joining today. And maybe we can start with a little company background.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
